Background: the role of neutrophil and lymphocyte counts as predictors of prognosis
Introduction
Community-acquired pneumonia (CAP) is a serious health problem causing high morbidity and mortality worldwide 1 . The rates of hospitalized patients due to CAP are increasing, with 22-42% of adults needing of admission to the hospital. CAP has an associated mortality of 5-14%. Around 5% of the patients hospitalized with CAP require admission to an intensive care unit (ICU). In these severe cases mortality raises to 35% 2 .
Host individual variability is now recognized as a key factor influencing clinical expression and prognosis of CAP 3 . Learning from the successes of utilizing precision medicine in the treatment of cancer, identifying individual phenotypes associated to poor outcome in CAP could help to understand better the pathogenesis of this disease and to improve its treatment 4 5 6 . In this regard, Davenport et al, using a transcriptomic analysis, found a gene expression signature (SRS1) which identifies individuals with an immunosuppressed phenotype and higher 14 day mortality within a cohort of patients with sepsis secondary to CAP 7 . In addition, new biomarkers like expression of HLA-DR on monocytes 8 , soluble CD14 (presepsin) 9 , interleukins 10 11 , procalcitonin 12 and mid-regional pro-ADM 13 could help risk assessment in the early moments of the disease. Alternatively to these new sophisticated (and expensive) "omics" and biomarker based approaches, a simple leukogram has shown to be a potential tool for classifying patients with CAP or sepsis based upon their outcome. The neutrophil/lymphocyte ratio (NLR) has been proposed as a candidate predictor of mortality for hospitalized CAP patients 14 .
In turn, we have demonstrated that septic shock patients who fail to expand circulating neutrophil counts in blood present an increased risk of mortality 15 .
Treatment options in CAP are still reduced to antibiotics and organ support in the most severe cases 16 . The important burden of morbidity and mortality associated to CAP has prompted investigations into a wide range of potential adjunctive immunological therapies 16 . Some of these therapies pretend to expand neutrophil counts 17 18 , while others are addressed to increase T cell counts and/or stimulate their function 19 20 21 . In our view, prior to the development of any further clinical trial with drugs expanding neutrophils or lymphocyte counts in blood, it would be necessary to elucidate whether or not they have any influence on the outcome of CAP patients.
The objective of the present study was to evaluate the impact of neutrophil and lymphocyte counts in blood on the mortality risk of patients with CAP and no antecedents of immunosupression. For this purpose, we performed a retrospective study in two large cohorts of hospitalized patients with this disease. Results of this work could help to clarify the potential role of neutrophil and lymphocyte counts on the development of precision medicine in CAP.
Methods

Study design:
data from two different cohorts of hospitalized patients with CAP (one recruited in the context of a multicentric study and the other in a unicentric study), were employed to evaluate in a retrospective manner, the association between neutrophil and lymphocyte counts at hospital admission with the risk of mortality at 30 days following discharge. Only those patients showing complete data on lymphocyte and neutrophil counts in the first 24 hours following admission to the hospital and the variables "admission to the ward/ICU", and "mortality at 30 days post-discharge from hospital"
were considered in the analysis. 
Other definitions:
In both studies, ARDS was identified in the first 24 hours after hospital admission by applying the criteria described in the Berlin definition 22 . 
Role of the funding source: the institutions supporting this work did not have any
role in the in study design, in the collection, analysis, and interpretation of data, in the writing of the report or in the decision to submit the paper for publication. (table 1) 
Results
Clinical characteristics of the patients
Analysis of mortality risk at 30 days following hospital discharge:
Multi-centric cohort: in the univariate analysis, the lymphocyte count was inversely associated to the risk of mortality (p < 0·05, Uni-centric cohort: as occurred in the multicentric cohort, in the univariate analysis the lymphocyte count was a protective factor against mortality (p < 0·05, , a similar prevalence of lymphopenia was observed at hospital admission (48·4% ). In our view, the high prevalence of lymphopenia in CAP has gone largely unnoticed until the present moment. Lymphopenia could be a cause or a consequence of CAP. Impaired production or increased apoptosis of lymphocytes caused by the presence of chronic diseases or critical illness 28 , enhanced adhesion to the vascular endothelium or massive migration of these cells to the lungs could explain the presence of lymphopenia in some patients with this disease.
Interestingly, we identified a sub-group of lymphopenic patients, those with lymphocyte counts below decil 3 (651 lymphocytes/mm 3 in the unicentric cohort and 677 lymphocytes/mm 3 in the multicentric one), which showed a 2-fold increase in the risk of mortality. This subgroup accounted with an increased proportion of critically ill patients and of those who developed complications (supplementary table 1 and 2). These patients had also a higher frequency of positive microbiological identification (supplementary table 1 
and 2). If this is consequence of a higher microbial load
secondary to a poor control of infection in these patients deserves to be investigated in future works. In consequence, our findings suggest that CAP patients with lymphocyte counts below decil 3 constitute a particular immunological phenotype of the disease which is associated with the presence of a more severe disease and worst outcome.
In the work from Marrie TJ and Wu L, a lymphocyte count < 1000 cell/mm 3 count was associated with early but not with late mortality. Nonetheless, there are a number of important differences between this work and ours. The most important is that Marrie TJ and Wu L excluded patients with leukocyte counts < 1000 cells/mm 3 and those with critical illness. In addition, they did not evaluate lymphocyte counts as a continuous variable to predict mortality, or other cut-offs below 1000 lymphocytes/mm3. Finally, they evaluated hospital mortality, not mortality at 30 days post-discharge as we did.
Early identification of patients at risk of death is a crucial step in the clinical management of the patients suffering from CAP 6 . For clinical operationalization, the mean value between both thresholds corresponding to decil 3 (664 lymphocytes/mm 3 )
could help to early recognize CAP patients at risk of poor outcome. Prompt identification of these patients could contribute to improve their prognosis, since they might benefit from more aggressive treatment strategies. In this regard, evaluation of lymphocyte counts is an inexpensive, widely available test in clinical settings worldwide.
Our results support also that lymphocyte counts should be taken into consideration as a potential confusion factor in the design and analysis of future clinical trials evaluating drugs or interventions for the treatment of CAP, since they influences prognosis. In addition, our findings suggest that patients with low lymphocyte counts could need of new therapeutic approaches, since the multivariate analysis demonstrated that the presence of low lymphocyte counts conferred an increased risk of mortality independently of receiving an appropriated antibiotic treatment and intensive care. In this regard, adjunctive therapy with drugs inducing expansion of lymphocyte counts and/or modulating function of these cells 19 20 21 could represent an option for these patients to be explored in future clinical trials, as actually occurs in sepsis: 1 4 NCT00711620 (Thymosin α 1), NCT02640807, NCT02797431 ( IL-7) or NCT02576457 (PD-L1 inhibitor) (ClinicalTrials.gov identifier).
The cohorts evaluated in this study differed in severity. This probably explained that the the upper threshold associated to mortality in the unicentric study, although being also in the range of lymphopenia, raised to 950 lymphocytes/mm 3 . Nonetheless, the threshold corresponding to decil 3 in both cohorts was very similar, evidencing that it was a preserved predictor of mortality independently of CAP severity at hospital admission. Far from representing a disadvantage, using heterogeneous cohorts could represent an opportunity. As supports the recent success of multicohort analysis and data sharing to discover new biomarkers in organ transplant, cancer, autoimmune and infectious diseases, studying heterogeneous cohorts makes that biomarkers that are discovered in these kind of cohorts are more likely to be generalizable across a broad spectrum of patients 29 . In this sense, our work is the first in utilizing two large cohorts and the same robust multivariate analysis to support the impact of lymphopenia on the outcome of patients with CAP.
Finally, our results showed that neutrophil counts were not associated with mortality risk in patients with CAP, raising doubts on the potential role of drugs aimed to expand neutrophils in this disease. In this sense, a systematic review from Cheng AC et al in 2007 concluded that the use of G-CSF as an adjunct to antibiotics was not associated with improved 28-day mortality 30 . In addition, at the light of the absence of any significant association between neutrophil counts with mortality, the potential value of the neutrophil to lymphocyte ratio as biomarker of mortality in CAP should be carefully re-evaluated.
A limitation of our work was its retrospective nature and the absence of data on lymphocyte subsets. The specific impact of CD4, CD8 T cells, B and NK lymphocytes on mortality should be studied in future prospective studies.
Conclusions
1. Lymphopenia is a very frequent finding in hospitalized patients with CAP and no immunosupression, being present in a half of the cases at admission. 2. Lymphopenic CAP with lymphocyte counts less than 664 lymphocytes/mm 3 constitutes a particular immunological phenotype of the disease which is associated with a two fold increase in the risk of mortality. 3. Assessing lymphocyte counts at hospital admission could contribute to personalize clinical management and treatment in CAP.
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Research in context
Evidence before this study: References for this article were identified through searches of PubMed for articles published in English before July 1 st 2017 by use of the terms "community acquired pneumonia" and "mortality", concomitant with the terms "biomarkers" OR "lymphocyte" OR "neutrophil" OR "adjuvant" OR "immunomodulatory therapy" OR "lymphopenia". The most representative articles corresponding to these items were cited and discussed. We only considered peer- acute renal failure and lymphopenia); one article corresponded to the only study similar to ours found in the literature, which is discussed in our article; finally, two articles were cited to discus on the impact of critical illness and chronic diseases on the immune system and the use of heterogeneous patients `cohorts for biomarker discovery. Initial ICU admission 1·67 1·08-2·58  0·021  1·46  0·94-2·27  0·089  1·48  0·96-2·28  0·080  1·53  0·99-2·36  0·054  1·55  1·01-2·39  0·047   Appropriate  antibiotic treatment   0·43  0·22-0·81  0·010  0·40  0·21-0·76  0·005  0·44  0·23-0·83  0·012  0·44  0·23-0·84  0·013  0·43 0·23-0·81 0·010
[Lymphocytes]
2·33 1·37-3·85  0·001  2·44  1·64-3·57  <0·001  2·33  1·61-3·33  <0·001  1·75  1·20-2·50  0·003  1·75  1·20-2·56  0·003 
